Despite technical refinements of the 120 W lithium-triborate laser fiber degradation and significantly decreased power output are still detectable during the procedure. Laser fibers are not fully appropriate for the high power delivery of the new system. There is still potential for further improvement in the laser performance. Therefore, the extent to which laser fibre degradation and loss of power output take place during 120W LBO-LV of the prostate was evaluated.
Introduction
Since its clinical introduction for prostatic de-obstruction in 1998, the 532nm greenlight laser system has experienced numerous modifications in order to optimize its performance. 1-3 The early low-powered 60W potassium-titanyl-phosphate (KTP) laser system was soon to be replaced by the more potent 80W system, which found a wide acceptance in urological practice at the beginning of this century.
2,4-7
Despite excellent clinical short-to mid-term results [8] [9] [10] [11] [12] several weak points of the procedure have also been identified. [13] [14] [15] Prolonged irritative voiding symptoms and post-operative urinary retention have been described as typical side effects of KTP-laser vaporisation (LV). 9, 15 Laser fibre degradation leading to a significant loss of power output during the operation has been identified as one possible reason for post-operative voiding problems. 13 The reduced power output results in inefficient tissue ablation and increased tissue coagulation. 16, 17 The latter is known to cause post-operative irritative voiding symptoms, whereas insufficient tissue ablation might impair the long-term efficacy of the procedure.
18,19
The typical problems of the KTP-laser called for further technical refinements. In 2006 the 120W high performance system (HPS) lithium triborate (LBO) laser has been introduced.
Higher power and modifications of the laser beam leading to a faster and more efficient noncontact vaporisation have been reported. 3 Surgically, an improved performance was clearly evident. However, macroscopic alterations of the fibre-tip and a decreasing ablative efficiency during the procedure again became apparent. The objective of the present investigation was to evaluate the performance of the HPS system with regard to structural changes of the laser fibre and associated changes in power output during treatment. surgeons (300-500 previous LV) and two novices performed the operations as described earlier. 13 The local ethics committee approved the study protocol (StV-Nr.16/2007) and all patients provided written informed consent.
Material and Methods

LBO-LV
Laser beam power measurements were performed at baseline and after the application of every 25kJ throughout the LV procedure. For the measurements, a custom-built fibre holder was used to hold the fibre in a fixed position (figs. 1, 2). After positioning of the fibre, the laser was shortly activated at 120W output power. After its emission from the fibre, the laser beam had to be attenuated to allow a precise measurement with a short release time (figs. 1, 3). Thus, the PM121 optical power meter (Thorlabs, Dachau, D) constantly measured 0.49% of the emitted power ( fig. 1 ).
For the analyses, the baseline value of each individual fibre was defined as 100%. Subsequent values in each measurement series were calculated and expressed as a percentage of this baseline value.
To investigate if the clinical estimation of the fibres` performance was in line with the results of the measurements, the surgeons stated when a decrease of the vaporisation efficiency became apparent during the operation and estimated the overall decrease of power output in percent after the operation. The surgeons were blinded to the results of the performed measurements. After the procedure the fibre-tip was microscopically examined and the degree of degradation was classified to be mild (i.e. superficial whitening), moderate (i.e. superficial melting) or severe (i.e. deep melting or complete destruction of the fibre-tip).
The impact of the surgeons' experience on the performance of the fibres during the operation was analysed by comparing the course of power output between two groups of patients operated by experienced or inexperienced surgeons, respectively.
Power measurements during non-contact in-vitro vaporisation were performed to investigate the performance of two fibres up to 275kJ in a setting without any fibre-tissue contact as described earlier. 13 Two additional fibres with only a baseline and a terminal measurement before and after a regular 275kJ-LV were investigated to further define the impact of the measurement procedure itself on the course of power output,.
Follow-up examinations were done 6 weeks and 6 months post-operatively. At each followup visit, subjective (International Prostate Symptom Score and quality of life) and objective outcome parameters (maximum flow rate, residual volume and PSA-value) were recorded.
Furthermore, patients were asked to report if bothering irritative voiding symptoms appeared.
Statistical analysis was performed using the Predictive Analytics Software version 18 (SPSS Inc, Chicago, IL, USA). Continuous variables were compared using the Wilcoxon signedrank test. All p-values <0.05 were considered significant. The course of power output of the two fibres tested in-vitro without fibre-tissue contact was similar to the course of the fibres tested in-vivo but the decrease of power output was less extensive. The median power output was 65% of the initial value after the application of 50kJ and 58.9% after the application of 275kJ.
Results
Intra
The decrease of power output of the two controls with only a baseline and an endpoint measurement was no different than that of the 46 regular measurements (data not shown).
The pre-operative prostate volume was not significantly different in the group of patients operated by experienced (group I) and inexperienced surgeons (group II). Although the lasing time was longer in group I, total operation time and applied total energy was significantly shorter (tab. 2). Median power output was slightly but significantly lower in group II after the application of 25 and 50kJ. Thereafter, power output was not significantly different anymore between the two groups (Fig. 7) .
The median duration of catheterization was 2 days (range: 1-13d) and the median postoperative hospital stay 4 days (2-25d). Four patients needed re-catheterization due to hematuria (n=2) or urinary tract infection with high post-void residual volume (n=2). One patient under oral anticoagulation needed transfusion due to persistent bleeding. Another 86-year-old patient died five days post-operatively due to cardio-pulmonal de-compensation.
After 6 weeks all investigated outcome parameters improved significantly and all patients were catheter-free (table 4) . Eleven patients (33%) reported irritative voiding symptoms. Two of those were diagnosed with a urinary tract infection. After 6 months all outcome parameters slightly improved further. Only three patients (11%) reported irritative voiding symptoms.
One of those was diagnosed with a persisting obstructive adenoma and received a conventional transurethral resection 6 months post-operatively.
Discussion
The clinical observation of a decreasing ablative efficiency associated with structural changes at the laser beam emission window during 120W LBO-LV has been substantiated in the present investigation. Fibre degradation resulted in a significant loss of power output throughout the operation with a total drop in power output of more than 50%.
Laser fibre deterioration and loss of power output have previously been reported for Nd:YAG-and KTP-laser treatment of the prostate. 13, [20] [21] [22] Heat at the tip of the fibre and insufficient heat resistance of the fibre itself are the main reasons for fibre degradation.
3,17
During KTP-LV heat accumulation at the fibre-tip is a result of adherent tissue debris and extensive fibre-tissue contact, which is difficult to avoid when performing LV with a recommended sweeping movement and an optimal fibre-tissue distance of only 0.5-1mm. 23 A constant decrease of power output throughout the operation with a final loss of power output of 80% was measurable during 80W KTP-LV. 13 Low power leads to a reduced ablative capacity, which in turn results in insufficient tissue ablation and increased tissue coagulation. 16, 17 The latter is a risk factor for irritative voiding symptoms, 18,19 while insufficient tissue ablation may result in early prostatic re-obstruction and thus may compromise the long-term efficacy of the procedure. Re-treatment rates up to 50% within 4 years have been reported after KTP-LV. 14 Bothersome post-operative voiding symptoms and high re-operation rates are well known problems after prostatic laser treatment and the main reasons preventing a breakthrough of several laser procedures in the past. 24 The novel features of the 120W HPS-laser were introduced to overcome the weaknesses of the KTP-laser. Higher power and an optimized laser beam profile, allowing for a more efficient tissue vaporisation and preventing early fibre degradation, have been reported.
3
Higher power together with an optimized laser beam collimation results in a higher power density and thus a stronger ablative capacity. The changes in beam characteristics additionally allow for efficient vaporisation at a greater distance from the tissue (1-3mm). This important innovation facilitates non-contact LV and consequently prevents fibre degradation and unwanted tissue coagulation. 23 The technical modifications markedly improved the performance of the system. The 120W HPS-laser has been shown to be 50% to 100% more efficient than the 80W KTP-laser invitro. [25] [26] [27] Fibre destruction and loss of power output observed in the present investigation are less vigorous than reported after KTP-LV. 13 This illustrates that not only the ablative capacity but also the performance throughout the procedure significantly differs between the two lasers. The relatively constant course of power output on a medium level after the initial decrease allows for a more constant performance towards the end of the fibre's lifespan From the clinical point of view, the decrease of power output seems to be relevant as well. In the present investigation 33% of the patients reported irritative voiding symptoms and one patient needed re-operation due to persisting adenoma during a six months follow-up period.
The typical side effects and need for re-operations have also been reported by others after HPS-LV. 28, 29 Most recently, the new 180W XPS laser system has been introduced. The HPS fibres can be used for the new system but only with 120W and not with 180W output power. Therefore, a novel fibre (MoXy™) with integrated water-cooling and a temperature-control sensor at the fibre-tip has been released. However, this fibre cannot be used for the 120W HPS-laser. It is desirable that the MoXy TM fibre meets the demands of XPS laser system and finally allows for a greenlight laser performance with a constantly high efficiency.
Some limitations of the present investigation deserve mention. Due to inhomogeneities of the laser fibres (e.g. position of the emission window, alignment of the positioning pin) the standardised set-up with its fixed fibre position might have generated the inter-fibre variances of the baseline power outputs to some extent. However, the exact measurement of the course of power output of the single fibres was guaranteed by this fixation. Furthermore, the extent of the structural and functional changes might only be valid for the operative technique performed in this investigation.
Conclusions:
The technical refinements of the 120W HPS-laser have been implemented in order to improve the tissue ablative properties and the longevity of the laser fibre. However, fibre degradation and a significant decrease of power output are still detectable during HPS-LV. This is mainly due to the laser fibres, which are not fully appropriate for the high power delivery of the new system. Thus, there is still potential for further improvement of the laser's performance. 
